This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Lfb Biotechnologies, National Institute of Health and Medical Research. Active years: 2014.
Company Filing History:
1 out of 10 
1 out of 1,853 
Years Active: 2014
Title: Suryasarathi Dasgupta: Innovator in Hemophilia Treatment
Introduction
Suryasarathi Dasgupta is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of biotechnology, particularly in the treatment of hemophilia A. His innovative work has led to the development of a unique patent that addresses critical challenges faced by patients with this condition.
Latest Patents
Dasgupta holds a patent for "Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A." This invention provides a modified Factor VIII with substantially decreased or abolished immunogenicity in humans. The modified factor VIII includes a changed amino acid sequence, altered by at least one substitution. This advancement is particularly beneficial for hemophiliacs, as it helps to avoid or prevent the action of inhibitory anti-FVIII antibodies.
Career Highlights
Throughout his career, Suryasarathi Dasgupta has worked with prominent organizations such as LFB Biotechnologies and the National Institute of Health and Medical Research. His experience in these institutions has allowed him to refine his expertise and contribute to groundbreaking research in the field of hemophilia treatment.
Collaborations
Dasgupta has collaborated with esteemed colleagues, including Sébastien Lacroix-Desmazes and Srinivas Kaveri. These partnerships have further enhanced his research and development efforts, leading to innovative solutions for patients suffering from hemophilia A.
Conclusion
Suryasarathi Dasgupta's contributions to biotechnology and hemophilia treatment exemplify the impact of innovation in healthcare. His patented work and collaborations highlight the importance of continued research in improving patient outcomes.